Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Effect of Oral Administration of Silymarin on Serum Levels of Tumor Necrosis Factor-Α and Interleukin-1ß in Patients With Rheumatoid Arthritis Publisher Pubmed



Shavandi M1, 2 ; Yazdani Y3 ; Asar S4 ; Mohammadi A5 ; Mohammadinoori E6 ; Kiani A7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Students’ Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran
  2. 2. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Clinical Trial Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
  4. 4. Department of Internal Medicine, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
  5. 5. School of Dentistry, Kermanshah University of Medical Sciences, Kermanshah, Iran
  6. 6. Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
  7. 7. Regenerative Medicine Research Center (RMRC), Kermanshah University of Medical Sciences, Kermanshah, Iran

Source: Iranian Journal of Immunology Published:2022


Abstract

Background: Rheumatoid Arthritis (RA) is a systemic chronic autoimmune disease. Several inflammatory agents play key roles in RA pathogenesis, among which tumor necrosis factor-alpha (TNF-α) and interleukin 1 beta (IL-1β) are of great importance. Silymarin is a potent anti-oxidant extracted from Silybummarianum L. seeds. Objective: To study the effect of silymarin on serum levels of TNF-α and IL-1β in patients with RA. Methods: Patients with stable RA received 140 mg of silymarin, 3 times a day, for 3 months. Serum samples were collected before and after the treatment. Both TNF-α and IL-1β serum levels were measured by ELISA. Results: 42 patients (14.3% male, and 85.7% female, with a mean age of 47.59±12.8 years old) completed the treatment course. There was no significant difference in the overall mean concentration of either TNF-α (P=0.14) or IL-1β (P=0.27) in all 42 patients after the treatment with Silymarin. Conclusion: The addition of Silymarin to the treatment regimen of patients with stable RA has no significant effect on the serum levels of TNF-α and IL-1β, however, this study needs further evaluation with a larger sample size. © 2022, Shiraz University of Medical Sciences. All rights reserved.